Related Experiment Video
Updated: Apr 29, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Multifactorial QT Interval Prolongation and Takotsubo Cardiomyopathy
Michael Gysel1, Alexander Crystal2, Jules C Hancox3
1Department of Medicine, Kingston General Hospital, Queen's University, Kingston, ON, Canada K7L 3N6.
Takotsubo cardiomyopathy (TCM) can cause acquired long QT syndrome (LQTS), leading to dangerous heart rhythms. This case shows TCM
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Takotsubo cardiomyopathy (TCM) is a form of non-ischemic cardiomyopathy.
- Acquired long QT syndrome (LQTS) is characterized by delayed ventricular repolarization.
- Torsades de pointes (TdP) is a specific ventricular arrhythmia associated with LQTS.
Purpose of the Study:
- To investigate the association between Takotsubo Cardiomyopathy and acquired Long QT Syndrome.
- To highlight the multifactorial nature of acquired LQTS.
Main Methods:
- Case report of a 71-year-old woman presenting with cardiac arrest.
- Analysis of electrocardiogram (ECG) findings, including QTc interval.
- Identification of contributing risk factors for LQTS.
Main Results:
- The patient experienced Torsades de Pointes (TdP) secondary to acquired Long QT Syndrome (LQTS).
- Takotsubo Cardiomyopathy was identified as a contributing factor to LQTS.
- Multiple risk factors, including age, female gender, hypokalemia, and QT-prolonging medications, were present.
Conclusions:
- Takotsubo Cardiomyopathy can be a cause of acquired LQTS.
- Acquired LQTS is often multifactorial, especially in elderly women with specific risk factors.
- Further research is warranted to explore the link between TCM and LQTS.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

